COVID-19 and isolation: Risks and implications in the scenario of new variants
Braz. j. infect. dis
;
26(5): 102703, 2022. tab
Artículo
en Inglés
|
LILACS-Express
| LILACS
| ID: biblio-1403892
ABSTRACT
Abstract With the emergence of new variants of SARS-CoV-2, questions about transmissibility, vaccine efficacy, and impact on mortality are important to support decision-making in public health measures. Modifications related to transmissibility combined with the fact that much of the population has already been partially exposed to infection and/or vaccination, have stimulated recommendations to reduce the isolation period for COVID-19. However, these new guidelines have raised questions about their effectiveness in reducing contamination and minimizing impact in work environments. Therefore, a collaborative task force was developed to review the subject in a non-systematic manner, answering questions about SARS-CoV-2 variants, COVID-19 vaccines, isolation/quarantine periods, testing to end the isolation period, and the use of masks as mitigation procedures. Overall, COVID-19 vaccines are effective in preventing severe illness and death but are less effective in preventing infection in the case of the Omicron variant. Any strategy that is adopted to reduce the isolation period should take into consideration the epidemiological situation of the geographical region, individual clinical characteristics, and mask for source control. The use of tests for isolation withdrawal should be evaluated with caution, due to results depending on various conditions and may not be reliable.
Texto completo:
Disponible
Índice:
LILACS (Américas)
Tipo de estudio:
Estudio de etiología
/
Guía de Práctica Clínica
/
Estudio pronóstico
/
Factores de riesgo
Idioma:
Inglés
Revista:
Braz. j. infect. dis
Asunto de la revista:
Enfermedades Transmisibles
Año:
2022
Tipo del documento:
Artículo
País de afiliación:
Brasil
Institución/País de afiliación:
Agência Nacional de Vigilância Sanitária (ANVISA)/BR
/
Associação Brasileira de Alergia e Imunologia/BR
/
Associação Brasileira dos Profissionais em Controle de Infecções e Epidemiologia Hospitalar/BR
/
Ministério da Saúde/BR
/
Ministério do Trabalho e Previdência/BR
/
Secretaria de Estado da Saúde de São Paulo/BR
/
Sociedade Brasileira de Cirurgia Oncológica/BR
/
Sociedade Brasileira de Infectologia/BR
/
Medicina Laboratorial+BR
/
Universidade Estadual Paulista (UNESP)/BR
Similares
MEDLINE
...
LILACS
LIS